Proteome Sciences to Commercialize Two Protein Biomarker Assays for Alzheimer's Disease
July 16, 2010
Proteome Sciences to Commercialize Two Protein Biomarker Assays for Alzheimer's Disease
The assays use multiple-reaction-monitoring mass spectrometry to measure the level of proteins associated with the disease and could be useful as diagnostic tests or research tools, said a company official.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Gothenburg Scientists ID Tyr10-Glycosylated A-beta as Potential Alzheimer's Biomarker
July 15, 2011 / ProteoMonitor - Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel
February 4, 2011 / ProteoMonitor - Proteome Sciences and Icon Collaborate on Mass Spec Assays for Pharma Biomarker Development
November 19, 2010 / ProteoMonitor - Study Suggests Flaws in Standard Cognitive Alzheimer's Test Could Undermine Drug, Biomarker Research
December 21, 2012 / ProteoMonitor - Proteome Sciences Completes 1,000-Patient Validation Study of Alzheimer's Plasma Protein Markers
March 30, 2012 / ProteoMonitor